Within the rapidly evolving fields of stem cells and regenerative medicine, there is an accelerating wave of activity. In the newsletter below, we summarize company news, industry research, and upcoming events.
Check it out and let me know what you think?
INDUSTRY ROUND-UP
Exosomes are produced by all cells in day to day bodily functions, but on a cell-for-cell basis, cancer cells release larger quantities of exosomes. Cancerous exosomes are tied up with chaperone proteins, which allow cancer cells to ignore normal rules, consume and utilize more nutrients and survive a self-polluted environment. Savvy researchers are now treating exosomes as "molecular mail," using these packages to determine the necessity and precision of therapy.
Gladstone Institutes Initiates Research Collaboration With Eli Lilly for Neurodegenerative Diseases
The Gladstone Institutes announced a new research collaboration with Eli Lilly focused on neurodegenerative diseases. This multi-year, milestone-driven project will be based on a combination of innovative technologies developed at Gladstone by Steve Finkbeiner, M.D., Ph.D. Key to the project is a robotic microscope system developed in Finkbeiner’s laboratory with funds from Gladstone, the Taube/Koret Center for Neurodegenerative Disease Research, and the ALS Association.
Role of Stem Cell Exosomes in Therapeutic, Diagnostic, and Drug Delivery Applications
Dr. Ramon Coronado, Executive Director at Lester Smith Medical Research Institute, started working with exosomes while looking for mechanisms used by MSCs to exert their therapeutic effects. In this interview, we discuss the scientific importance of exosomes, therapeutic and diagnostic applications of exosomes, and their use within encapsulation/delivery systems. We also explore advantages and disadvantages of exosomes, as compared to cell therapeutics.
Avalon GloboCare Acquires Leading Beijing Exosome Technology Company
Avalon GloboCare Corp. (OTCQB: AVCO) announced that its majority-owned subsidiary GenExosome Technologies acquired 100% of the outstanding capital stock of Beijing Jieteng (Beijing GenExosome) Biotech Co. Ltd. It also entered into an Asset Purchase Agreement with the CEO, Dr. Yu Zhou, to acquire all assets and IP held by Dr. Zhou pertaining to researching, developing, and commercializing exosome technologies.
StemBioSys Announces New European Distributor For Stem Cell Research Products
StemBioSys Inc. has entered into an agreement with Caltag Medsystems Ltd. to distribute and market StemBioSys products. Caltag will distribute StemBioSys products in the European Union. Initially, the agreement will cover StemBioSys’ cell expansion products, but as additional products are added to the company's portfolio, they will likely be included in the distribution agreement.
Dubai First to Launch Innovative Stem Cell Therapy for Joint Disease
Bioscience Clinic FZ LLC located in Dubai Healthcare City has launched its latest innovative therapy for treatment of joint disease. Established since 2012, Bioscience Clinic is Dubai’s first and most advanced clinic to use stem cells taken from adipose tissue in a variety of clinical applications. Its latest therapy was first introduced in Europe by Bioscience Institute in partnership with the University of Rome, a Bioscience Clinic sister company.
Academic and Medical CDMOs Serving the Cell Therapy Industry
In addition to commercial cell therapy CDMOs, there are other industry players who support the cell therapy industry, including academic and medical CDMOs. Leading academic CDMOs include Waisman Biomanufacturing's facility within the Waisman Center at UW–Madison, the Center for Advanced Cellular Therapeutics at Penn Medicine, Stanford’s Lab for Cell and Gene Medicine in Palo Alto, and more.
Cord Blood Industry Trends – Clinical Trials, Publications, Patents, Grants, & More
With the cord blood industry maturing and consolidating, numerous cord blood banks have either been acquired or gone out of business. However, this era of maturation and consolidation has had as many benefits to surviving cord blood banks as drawbacks. On average, the remaining market participants are now larger, stronger, better capitalized, and storing larger quantities of cord blood and tissue units than when the market was more fragmented.
INDUSTRY RESEARCH
Market Size Determination for the Cord Blood and Cord Tissue Industry
Within the global cord blood banking market, a small number of industry giants control the majority of the market share. Cord blood and tissue units stored by industry leaders include: Sanpower Group (1,100,000 units), Cord Blood Registry (700,000 units), Cryo-Cell International (420,000 units) ViaCord (360,000 units) Cryo-Save (268,000 units), and more. To provide comprehensive market coverage, this 23-page report that defines the size of the Cord Blood and Tissue Banking Market and provides projections through 2022.
Market Size Determination for the Cell Therapy CDMO Market
Among cell therapy companies, the pressure for manufacturing innovation and optimization can incentivize them to seek third-party partners who possess technical, manufacturing, and regulatory expertise, such as cell therapy contract and development manufacturing organizations (CDMOs). For this reason, this 20-page market brief defines the size of the Cell Therapy CDMO Market and provides future market projections.
Rates of U.S. Cord Blood and Cord Tissue Storage – Historic and Projected
Curious to know rates of cord blood and cord tissue storage in the U.S. over the past 10 years? Interested to see market projections for the next 5 years? For the first time ever, you can access to historical and projected U.S. market data in an Excel spreadsheet, with an accompanying description of the market forces that have impacted and will impact the market in the future.
Today, several trends are impacting the cord blood banking marketplace, including holding companies emerging as a global theme, cord blood banks diversifying into new types of perinatal tissues, coupling of prenatal and newborn genetic testing services, and high rates of industry consolidation. There is also accelerating investment flowing into cord blood expansion technologies, led by progress at Gamida Cell Ltd, Nohla Therapeutics, Plasticell, Novartis, Fate Therapeutics, and Magenta Therapeutics.
The Market for Stem Cell Exosomes
This 134-page global strategic report reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials, as well as social analytics from Google Trends and Google Adwords. It explores the growing demand for exosome therapeutics, diagnostics, research tools, consumer care products, and manufacturing processes. It identifies the five market segments forming the industry, reveals the market player competing in each niche, presents market size determinations with 5-year projections, and identifies opportunities for commercializing exosome products.
UPCOMING EVENTS
This year Phacilitate's Cell and Gene Therapy World will be co-locating with the World Stem Cell Summit and featuring a Cord Blood & Perinatal Stem Cells track, Chaired by BioInformant's President, Cade Hildreth. The conference will be the world's largest event dedicated to Advanced Therapies and Regenerative Medicine with 1,200+ attendees, 280+ speakers, and 150+ exhibitors. Use the code "BIO10" to get 10% off your registration.
Join this annual conference to access cutting-edge research from pioneers across the stem cell field, cultivate relationships with engaged colleagues, and learn from leading clinicians utilizing cellular therapies within their practices. The field of perinatal stem cells is exploding, with massive innovation centering around placental therapies, as well as umbilical cord blood, umbilical cord tissue, and amniotic products. Use the code "BIOI" to get $100 off your registration and let me know if I will see you there?
Be Great,
Cade President/CEO of BioInformant.com "1st and Only Market Research Firm to Specialize in the Stem Cell Industry"
p.s. Have stem cell news to share? Hit "reply" to this email to send it to me.
|
|
|
